One Step Closer to Saying Goodbye to Peanut Allergy

Peanut allergy prevention: Newly developed allergen-specific inhibitor has successfully prevented potentially life-threatening allergic responses to peanuts in mice.

Peanut allergy is life-threatening and finding a solution to prevent allergic responses to peanuts can save lives.

An allergen-specific inhibitor devised by researchers at the University of Notre Dame and the Indiana University School of Medicine has successfully prevented potentially life-threatening allergic responses to peanuts.

Early Introduction of Peanuts in Babies Decrease Allergy Risk
Early introduction of peanuts in infants can lessen the peanut allergy risk, reveals a new study.

‘Newly developed allergen-specific inhibitor could one day keep peanut allergy at bay.’
Read More..

The results of the new study were just published in Science Translational Medicine.

Is Peanut Allergy Dangerous?

Peanuts cause severe, sometimes fatal, reactions in an estimated 1.1 percent of the global population. Strict dietary avoidance is the most common therapy for peanut allergies, but the risk of accidental exposure is high. There are currently no therapies to prevent allergic events from happening in the first place.

"Our approach is unique because our inhibitor starts working before the allergen has a chance to trigger an allergic reaction," said Başar Bilgiçer, professor of chemical and biomolecular engineering at the University of Notre Dame.

“Our collaboration with Dr. Mark Kaplan at Indiana University School of Medicine and Dr. Scott Smith at Vanderbilt University Medical Center made the development of these inhibitors possible. With their help, we were able to demonstrate the potency of our approach in animal studies.”

How to Prevent Peanut Allergy?

Using a covalent heterobivalent inhibitor(cHBI)that they designed in their previous work, the researchers prevented allergic reactions in mice with human immune cells. A single administration provided protection against peanut allergic reaction for over two weeks. Moreover, when given shortly after the onset of symptoms, the inhibitor stopped the progression of the allergic reaction in its tracks.

Few Peanut Allergy Patients Tolerate Peanuts after Immunotherapy
New Phase 2 study, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, informs who benefit from peanut oral immunotherapy(OIT).

When IgE antibodies and peanut allergens interact in an allergic person’s bloodstream, inflammatory mediators such as histamine are released in large quantities throughout the body.

"The release of histamines is meant to fight against invading pathogens, but, in the case of peanut allergy, there is no pathogen, just peanut proteins,” said Bilgiçer.

Immunotherapy for Peanut Allergy Provides Protection but Not a Cure: Study
Researchers tested samples from patients who suffer from peanut allergy with peanut oral immunotherapy (POIT) and revealed that it does not stop them being allergic just suppresses the reaction.

The new inhibitor effectively masks the immune system’s ability to recognize the allergen, allowing it to fly under the immune system’s radar without initiating a dangerous response or compromising its ability to fight real pathogens.

The researchers developed inhibitors specifically for peanut allergy because it is the most common food allergy, with high prevalence, especially in children. Nevertheless, the success of cHBI in this study paves the way for the development of other allergen-specific inhibitors.

People with Peanut Allergies can Eat Tree Nuts but Choose Not To: Study
People with peanut allergies can eat tree nuts but choose to avoid it. The most common reason for avoidance was to minimize the risk of cross-contact, reports a new study.

“What we’ve developed is a platform technology,” said Bilgiçer. “The same design and engineering principles used in this paper can be applied in developing inhibitors to treat a range of other allergies such as shellfish and penicillin.”

The research will now advance to preclinical trials.

Source-Eurekalert